We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Twice too aggressive by half

20 April 2007 By Robert Cyran

The biotech giant s sale of $5bn worth of cheap convertible debt to buy back stock looked mighty smart last year. The only problem the stock is down 12% since because Amgen s attempt to expand its main drug into a minor area blew up in its face.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)